3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
von Hippel-Lindau Disease
1
Ulcer
1
Smoldering Multiple Myeloma
1
Skin Neoplasms
1
Sarcoma, Kaposi
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Liver Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioma, Capillary
1
Hemangioblastoma
1
Fallopian Tube Neoplasms
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
3
Doxorubicin
3
Standard of Care
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Watchful Waiting
1
Trastuzumab
1
STA 9090
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hemangiosarcoma
×
Propranolol
×
Clear all
NCT05961761
2023-07-27
PROPANE
Herlev and Gentofte Hospital
Phase 2
Recruiting
80 enrolled